All News

What We’re Reading: CMS Finalizes Protections for MA, Part D Enrollees; Prescription Digital Treatment for MDD; Paxlovid Shows Limited Efficacy in Fully Vaccinated Individuals

CMS finalizes policies to enhance consumer protections, promote competition, and expand access to care for Medicare Advantage (MA) and Medicare Part D; digital therapeutic Rejoyn receives FDA clearance for adults with major depressive disorder (MDD); study reveals minimal symptom reduction from nirmatrelvir–ritonavir (Paxlovid) in high-risk, fully vaccinated patients.